Dosing & Administration

Oral and IV Monotherapy Dosing
With BAXDELA® (delafloxacin)

Oral or IV q12h dosing

Baxdela dosing table

No Oral Dosage Adjustment Required Due To:

image group referencing age(adult), weight, sex
image group referencing mild to moderate renal disease, hepatic disease

Oral or IV BAXDELA is not recommended in patients with End Stage Renal Disease (ESRD) (eGFR <15 mL/min/1.73 m2), including patients on hemodialysis, due to insufficient information for dosing recommendations.

Fixed-Dosage Adjustment in IV Formulation for Patients with Severe Renal Impairment (eGFR 15-29 mL/min/1.73 m2)

  • 200 mg IV q12h


  • 200 mg IV q12h, then switch to a 450-mg BAXDELA tablet orally q12h at the discretion of the physician
BAXDELA® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.